Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Nurse Practitioner August 2011 Davis et al.	Supportive approaches for Alzheimer Disease Alzheimer disease accounts for almost 80% of all dementia diagnoses. Currently, more than 5 million Americans suffer from this debilitating illness, with the highest prevalence in the oldest age groups.
American Family Physician March 15, 2004	STEPS Memantine (namenda) for moderate to severe alzheimer's disease
The Motley Fool May 30, 2006 Rich Duprey	NICE Not Playing Nice With Alzheimer's The British health authority proposes limiting availability of Alzheimer's treatments because of cost. What will this mean to drug-makers and their shareholders?
The Motley Fool October 13, 2006 Rich Duprey	NICE Is Just Dumb The British health agency prohibits the use of certain Alzheimer's treatments because of cost.
Chemistry World October 8, 2010 Sarah Houlton	U-turn on Alzheimer's drugs in the UK The UK National Institute for Health and Clinical Excellence proposes that those with mild disease will be able to receive them from early next year, on the basis of growing clinical evidence of their effectiveness.
American Family Physician June 15, 2002 Jeffrey L. Cummings	Guidelines for Managing Alzheimer's Disease: Part II. Treatment Once the clinical diagnosis of Alzheimer's disease has been made, a treatment plan must be developed. Patient symptoms and care needs change as Alzheimer's disease progresses.
Chemistry World November 2, 2006 Michael Gross	Alzheimer's Century Researchers worldwide are commemorating the centenary of Alois Alzheimer's first description of the dementia named after him.
The Motley Fool October 10, 2011 Frank Vinluan	TRGT Tries Again With Alzheimer's Disease Drug Candidate A Targacept compound that has been studied in a range of cognitive disorders with drug partner AstraZeneca has started in mid-stage clinical studies as a potential new Alzheimer's disease treatment.
The Motley Fool June 29, 2007 Rich Duprey	No More Mr. NICE Guy Pharmaceuticals take British advisory agency to court to approve Alzheimer's treatment.
American Family Physician June 1, 2002 Jeffrey L. Cummings	Guidelines for Managing Alzheimer's Disease: Part I. Assessment Family physicians play a key role in assessing and managing patients with Alzheimer's disease and in linking the families of these patients to supportive services within the community.
American Family Physician October 1, 2003 Vincent W. Delagarza	Pharmacologic Treatment of Alzheimer's Disease: An Update Alzheimer's disease is characterized by the development of senile plaques and neurofibrillary tangles, which are associated with neuronal destruction, particularly in cholinergic neurons. Drugs that inhibit the degradation of acetylcholine within synapses are the mainstay of therapy.
Pharmaceutical Executive January 1, 2013 Al Topin	The Doctor-Patient Disconnect Doctor-patient conversations aren't always what we think; this basic interaction represents both a problem and an opportunity for today's drug marketers, says the author.
Nursing June 2011 Cahill & Armstrong	Caring for an adult with a malignant primary brain tumor Pprimary brain tumors are relatively uncommon, occurring in an estimated 63,000 patients in the united states each year.
Chemistry World August 9, 2012	Bapineuzunab dropped Pfizer and Johnson and Johnson have announced that they are ending development of the intravenous Alzheimer's drug bapineuzumab after it failed in two clinical trials.
The Motley Fool August 27, 2007 Rich Duprey	Japan Is Serious About Alzheimer's While Britain limits access, Japan expands coverage of the top-selling treatment for Alzheimer's. Japan's regulators made the decision following a six-month study comparing Aricept with a placebo.
Pharmaceutical Executive September 1, 2012 Al Topin	Doctors' Words No Longer Gospel In the digital age, physicians don't call the shots when it comes to healthcare guidance. Marketers must appeal to multiple sources in seeking ways to garner patient adherence and loyalty.
The Motley Fool September 2, 2005 Rich Duprey	An Opportunity Not to Forget Japanese pharmaceutical Eisai targets another segment of the growing Alzheimer's market. Investors, take note.
Pharmaceutical Executive February 1, 2012 Sarah Krug	Introducing the 'Chief Patient Officer' Now is the time for pharma companies to appoint a Chief Patient Officer, a new position designed to build an accord around patient trust.
The Motley Fool August 10, 2010 Ryan McBride	Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive.
The Motley Fool September 5, 2008 Brian Lawler	Why Pfizer Made an Interesting Blockbuster Bet The pharma giant inked a deal worth potentially more than $725 million with development stage drugmaker Medivation to market Medivation's Alzheimer's disease drug Dimebon.
CIO October 29, 2015 Martha Heller	Amgen uses algorithms to venture into digital healthcare A senior vice president of global marketing and commercial development, says she's working with the CIO to set up a digital healthcare organization that can help physicians better predict how patients will respond to therapies.
Chemistry World July 20, 2012 Michael Parkin	New supramolecular Alzheimer's drugs Supramolecular chemistry could provide a new avenue in the treatment of Alzheimer's disease, say scientists in China.
Chemistry World July 3, 2014 Maria Burke	Renewed focus on dementia checked by drug challenges The risks and barriers for companies working in dementia are huge, but so too, potentially, are the rewards, says Simon Ridley, head of research at Alzheimer's Research UK.
Chemistry World December 19, 2012 Amy Middleton-Gear	Early Alzheimer's diagnosis compound UK and US scientists have developed a labelled tracer compound that binds to plaques closely associated with Alzheimer's disease so that the plaques can be picked up by a medical imaging technique.
Chemistry World May 27, 2015 Phillip Broadwith	Actavis plan to thwart generics blocked A US court has blocked Ireland-based firm Actavis's attempt to forcibly shift patients onto an extended release version of one of its drugs by withdrawing the original formulation from the market.
Chemistry World March 31, 2014 Kirsty Muirhead	Zinc ruled out as biomarker for Alzheimer's disease Scientists in Australia have added to evidence that no change in serum zinc concentration is seen in AD, and that decreasing zinc levels are instead a sign of ageing.
Pharmaceutical Executive September 1, 2012 Robin Hertz	The Endless Treadmill of End-of-Life Care Bending the cost curve back to valuing the cycle of life.
Pharmaceutical Executive October 1, 2011	Patient Advocacy: The Last 30 Years The rise of advocacy groups has helped patients find their voice, but the power to change health profiles remains an elusive goal.
The Motley Fool October 18, 2006 Rich Duprey	FDA Expands Alzheimer's Treatment Japan's fourth-largest pharmaceutical Eisai's Aricept wins the right to treat all stages of Alzheimer's. Investors, take note.
Nursing April 2012 Elliott et al.	Managing alcohol withdrawal in hospitalized patients A focused nursing assessment is critical in identifying the potential for alcohol withdrawal symptoms in all hospitalized patients. This article discusses how to assess patients at risk and how to use these assessment findings as a basis for nursing interventions.
American Family Physician December 15, 2000 Susan Mockus Parks & Karen D. Novielli	A Practical Guide to Caring for Caregivers Patients who provide care to family members or friends with dementia are likely to be in a family physician's practice. The caregiver role can be stressful, and identifying these patients can give the family physician opportunities to help patients cope with the challenges of the role...
American Journal of Nursing December 2011 Mary K. Walton	Supporting Family Caregivers: Communicating with Family Caregivers A transformation is under way in acute care, at least in the United States, from provider-centered care to patient- and family-centered care.
Pharmaceutical Executive April 1, 2011	Bridging the HCP-Patient Gap Here's what's necessary to bridge the gap between the patient revolution and healthcare provider in the 21st century.
American Journal of Nursing November 2011	Supporting Family Caregivers: Teaching Essential Skills to Family Caregivers Nurses can use 'teachable moments' to help the transition from hospital to home care.
The Motley Fool August 17, 2010 Brian Orelli	Forget About This Drug Saving the Company Lilly's Alzheimer's drug fails hard.
AskMen.com Jacob Franek	Alzheimer's Disease 101 It's only in the last decade or so that we have truly come to understand the various disorders of the brain that are associated with age and, in most cases, Alzheimer's disease is the prime suspect. Read on for some basic information.
The Motley Fool August 13, 2007 Rich Duprey	U.K. High Court Forgets to Be NICE A court challenge to place limits on treatment for Alzheimer's disease is upheld. Eisai has said it will appeal the High Court's ruling. It's a bit of a high-stakes gamble. The United Kingdom accounts for just a small portion of Eisai's profits from Aricept.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	Alzheimer's: A Disease at a Crossroads The need for new drugs intensifies as more and more Baby Boomers live into advanced old age. The global market is estimated to be worth $20 billion by the end of the decade.
Chemistry World October 14, 2009 Phil Taylor	Tracing amyloid in Alzheimer's A diagnostic compound that allows researchers to look into the brains of Alzheimer's patients will be used for the first time to gauge the effects of an experimental therapy for the disease.
Nursing February 2010 Daniel A. Hussar	New Drugs 2010, PART 1 In this article, you'll learn about 16 new drugs.
Fast Company September 14, 2011 Emma Haak	Global E-Health Forum Protecting patients' medical information in the digital age is no easy feat.
Financial Planning August 1, 2009 Donna Mitchell	Alzheimer's Toll A study surveyed 369 advisors in the U.S. to gauge their understanding of Alzheimer's and their preparedness for dealing with clients who have the disease.
Nursing March 2012 Daniel A. Hussar	New Drugs 2012: part I In this article, you'll learn about 11 recently approved drugs.
Pharmaceutical Executive August 1, 2011 Jennifer Ringler	The Adherence Fight: A TKO? Why does the match against medicines compliance always seem to end in an easy knockout?
Pharmaceutical Executive October 1, 2010	Optimizing TV Advertising Placements & Results Brand managers choosing to advertise an anti-depressant on "Criminal Minds" may not be making the best choice. New methodologies reveal "Law & Order: Special Victims Unit" along with "The Bachelor" to be shows favored by depressives.
Nursing February 2009 Daniel A. Hussar	New Drugs 09: Part 1 Learn about 10 new drugs, including nebivolol HCl, the newest beta-adrenergic blocking agent for hypertension.
American Family Physician December 15, 2000	When You Are the Caregiver You're a caregiver if you give basic care to a person who has a chronic medical condition. How can I tell if caregiving is putting too much stress on me?... Why is caring for someone with dementia (Alzheimer's disease) so hard?... etc.
Nursing June 2011 Daniel A. Hussar	New Drugs 2011: Part 2 In this article, you'll learn about seven recently approved drugs, including: fingolimod hydrochloride, an oral drug indicated to treat patients with relapsing forms of multiple sclerosis.
Pharmaceutical Executive November 1, 2012 Sue Barrowcliffe	Real World Insights Commercial teams as well as patients can benefit from managed access programs, which are designed to provide access to medicines outside of the clinical and commercial setting, for patients who have no other available treatment options.
Search Engine Watch December 31, 2010 Dean Stephens	Health Gets Social in 2010 The role of social media in search results is influencing how health organizations attract and treat patients.